Shares of AnaptysBio (ANAB) are plummeting after earnings slides from Eli Lilly (LLY) showed the company removed peresolimab, a PD-1 agonist, from its mid-stage pipeline. AnaptysBio is developing its own PD-1 agonist, rosnilimab. The shares in premarket trading are down 31%, or $9.44, to $21.69.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB: